ClarivateCLVT
CLVT
About: Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.
Employees: 12,000
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
71% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 31
69% more call options, than puts
Call options by funds: $725K | Put options by funds: $430K
14% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 58
10% more funds holding
Funds holding: 192 [Q4 2024] → 211 (+19) [Q1 2025]
0.29% less ownership
Funds ownership: 89.32% [Q4 2024] → 89.03% (-0.29%) [Q1 2025]
25% less capital invested
Capital invested by funds: $3.22B [Q4 2024] → $2.41B (-$813M) [Q1 2025]
27% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 8 (-3) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4.50
11%
upside
Avg. target
$4.50
11%
upside
High target
$4.50
11%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Jefferies Surinder Thind | 11%upside $4.50 | Hold Downgraded | 18 Jul 2025 |
Financial journalist opinion
Based on 7 articles about CLVT published over the past 30 days
Neutral
Seeking Alpha
7 hours ago
Clarivate Plc (CLVT) Q2 2025 Earnings Call Transcript
Clarivate Plc (NYSE:CLVT ) Q2 2025 Earnings Conference Call July 30, 2025 9:00 AM ET Company Participants Jonathan M. Collins - Executive VP & CFO Mark J.
Neutral
Zacks Investment Research
9 hours ago
Here's What Key Metrics Tell Us About Clarivate (CLVT) Q2 Earnings
While the top- and bottom-line numbers for Clarivate (CLVT) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Zacks Investment Research
11 hours ago
Clarivate PLC (CLVT) Q2 Earnings Match Estimates
Clarivate PLC (CLVT) came out with quarterly earnings of $0.18 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.2 per share a year ago.
Neutral
PRNewsWire
13 hours ago
Clarivate Announces Maroun S. Mourad as President, Intellectual Property
LONDON , July 30, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced that Maroun S. Mourad will join the Company as President of the Intellectual Property (IP) segment, effective September 8, 2025.
Neutral
PRNewsWire
13 hours ago
Clarivate Reports Second Quarter 2025 Results
— Continued acceleration of organic ACV and recurring organic revenue growth — — Delivered improved organic recurring revenue mix — — Reaffirmed 2025 Outlook — — Repurchased 11.5 million ordinary shares in the second quarter— LONDON , July 30, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the second quarter ended June 30, 2025. Total revenues for the second quarter of 2025 were $621.4 million, compared to total revenues of $650.3 million for the second quarter of 2024, due to inorganic divestitures and disposals.
Neutral
PRNewsWire
3 weeks ago
Clarivate Releases 2025 G20 Research and Innovation Scorecard Highlighting Global Collaboration and Impact
New Data Reveals Shifting Global Partnerships, Rising Open Access, and Focus on SDG-Aligned Research LONDON , July 9, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today published its annual G20 research and innovation scorecard, developed by expert analysts and data scientists at the Institute for Scientific Information (ISI) at Clarivate. This interactive scorecard offers a comprehensive, data-driven view of the research and innovation capabilities of G20 member nations.
Neutral
PRNewsWire
3 weeks ago
Clarivate to Report Second Quarter 2025 Results on July 30, 2025
LONDON , July 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the second quarter 2025 before the market opens on Wednesday, July 30, 2025. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com.
Neutral
PRNewsWire
1 month ago
Clarivate Unveils the 2025 Journal Citation Reports
50th Anniversary Year Sees Strengthened Focus on Research Integrity LONDON , June 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the 2025 update to the Journal Citation Reports (JCR). This is the 50th anniversary of the industry-leading annual reports, which provide a comprehensive overview of the world's leading and trusted academic journals, offering academic institutions, researchers, and publishers the ability to gauge journals' trustworthiness and impact.
Neutral
PRNewsWire
1 month ago
Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology
New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON , June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new Companies to Watch report, Radioligand Innovators Ushering in a New Era of Precision Oncology . The report spotlights pioneering companies that are redefining the drug discovery and development landscape through advancements in radioligand therapies (RLTs)—a rapidly evolving class of therapeutics that combines nuclear medicine with precision-targeted biotechnology to treat cancer with heightened specificity.
Neutral
PRNewsWire
1 month ago
Clarivate Partners with American Library Association to Advocate for U.S. Libraries
LONDON , June 9, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a new milestone in its decades-long partnership with the American Library Association (ALA). Clarivate will be the first sponsor of the ALA Public Supporter Program, which engages the public in supporting libraries and library professionals.
Charts implemented using Lightweight Charts™